Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection

Patent metadata

Field	Value
Publication number	US-9763970-B2
Application number	US-201113335404-A
Country	US
Kind code	B2
Filing date	Dec 22, 2011
Priority date	Dec 31, 2010
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

First claim

What is claimed is:

1. A method for treating enteric viral infection in an infant, toddler, or child in need thereof, the method comprising administering to an infant, toddler, or child a nutritional composition comprising from about 0.01 mg/mL to about 10 mg/mL of a human milk oligosaccharide and from about 40 mg/L to about 320 mg/L of total nucleotide, wherein the enteric viral infection is a rotavirus induced infection.

2. The method of claim 1 , wherein the human milk oligosaccharide is a neutral human milk oligosaccharide or an acidic human milk oligosaccharide.

3. The method of claim 2 , wherein the neutral human milk oligosaccharide is lacto-N-neotetraose.

4. The method of claim 2 , wherein the acidic human milk oligosaccharide is selected from the group consisting of 3′-sialyllactose, 6′sialyllactose, sialic acid, and combinations thereof.

5. The method of claim 4 , wherein the human milk oligosaccharide comprises about 40 wt % 6′-sialyllactose, about 10 wt % 3′-sialyllactose, and about 50 wt % sialic acid, based on the total weight percentage of human milk oligosaccharides.

6. The method of claim 1 , wherein the nucleotide is selected from the group consisting of cytidine 5′-monophosphate, uridine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and combinations thereof.

7. The method of claim 1 , wherein the composition comprises from about 40 mg/L to about 72 mg/L of total nucleotide.

8. A method of reducing the likelihood that an infant, toddler, or child becomes symptomatic due to an enteric virus or for ameliorating symptoms due to an enteric viral infection in an infant, toddler, or child infected with an enteric virus, the method comprising administering to an infant, toddler, or child a nutritional composition comprising from about 0.01 mg/mL to about 10 mg/mL of a human milk oligosaccharide and from about 40 mg/L to about 320 mg/L of total nucleotide, wherein the enteric viral infection is a rotavirus induced infection.

9. A method for treating enteric viral infection in an infant, toddler, or child in need thereof, the method comprising administering to an infant, toddler, or child a nutritional composition comprising from about 0.01 mg/mL to about 10 mg/mL of a human milk oligosaccharide selected from the group consisting of lacto-N-neotetraose, 3′-sialyllactose, 6′-sialyllactose, sialic acid, and combinations thereof, and from about 40 mg/L to about 320 mg/L of total nucleotide, wherein the enteric viral infection is a rotavirus induced infection.

Assignees

• Buck Rachael
• Thomas Debra L
• Schaller Joseph P
• Abbott Lab

Inventors

• Buck Rachael
• Thomas Debra L
• Schaller Joseph P

Classifications

• A23V2200/32

  having an effect on the health of the digestive tract · CPC title

• A61K31/702 Primary

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title

• A23L33/40

  Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

• A23V2250/284

  Oligosaccharides, non digestible · CPC title

• A61K31/708

  having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid · CPC title